Immune Modulators with Defined Molecular Targets: Cornerstone to Optimize Rational Vaccine Design

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 655)


Vaccination remains the most valuable tool for preventing infectious diseases. However, the performance of many existing vaccines should be improved and there are diseases for which vaccines are still not available. The use of well-defined antigens for the generation of subunit vaccines has led to products with an improved safety profile. However, purified antigens are usually poorly immunogenic, making essential the use of adjuvants. Despite the fact that adjuvants have been used to increase the immunogenicity of vaccines for more than 70 years, only a handful has been licensed for human use (e.g., aluminium salts, the micro-fluidized squalene-in-water emulsion MF59 and monophosphoryl lipid A). Thus, the development of new adjuvants which are able to promote broad and sustained immune responses at systemic and mucosal levels still remains as a major challenge in vaccinology. Recent advances in our understanding of the immune system have facilitated the identification of new biological targets for screening programs aimed at the discovery of novel immune stimulators. This resulted in the identification of new candidate adjuvants, which made possible the modulation of the immune responses elicited according to specific needs. A number of promising adjuvants which are currently under preclinical or clinical development will be described in this chapter.


West Nile Virus Innate Immune System Cholera Toxin Costimulatory Molecule Francisella Tularensis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Agrawal S, Agrawal A, Doughty B et al. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol 2003; 171(10):4984–9.PubMedGoogle Scholar
  2. 2.
    Athman R, Philpott D. Innate immunity via Toll-like receptors and Nod proteins. Curr Opin Microbiol 2004; 7(1):25–32.PubMedGoogle Scholar
  3. 3.
    Dziarski R, Gupta D. Peptidoglycan recognition in innate immunity. J Endotoxin Res 2005; 11(5):304–10.PubMedGoogle Scholar
  4. 4.
    Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006;442(7098):39–44.PubMedGoogle Scholar
  5. 5.
    Scott AM, Saleh M. The inflammatory caspases: guardians against infections and sepsis. Cell Death Differ 2007; 14(1):23–31.PubMedGoogle Scholar
  6. 6.
    Dutton RW. In vitro studies of immunological responses of lymphoid cells. Adv Immunol 1967; 6:253–336.PubMedGoogle Scholar
  7. 7.
    Unanue ER, Askonas BA. The immune response of mice to antigen in macrophages. Immunology 1968; 15(2):287–96.PubMedGoogle Scholar
  8. 8.
    Buchan GS, Young SL, Lockhart EA et al. Targeting early events in T-cell activation to construct improved vaccines. Mol Immunol 2000; 37(9):545–52.PubMedGoogle Scholar
  9. 9.
    Allison AC. Immunological adjuvants and their modes of action. Arch Immunol Ther Exp (Warsz) 1997; 45(2–3):141–7.Google Scholar
  10. 10.
    Vajdy M, Srivastava I, Polo J et al. Mucosal adjuvants and delivery systems for protein, DNA-and RNA-based vaccines. Immunol Cell Biol 2004; 82(6):617–27.PubMedGoogle Scholar
  11. 11.
    Honma K, Abraham JL, Chiyotani K et al. Proposed criteria for mixed-dust pneumoconiosis: definition, descriptions and guidelines for pathologic diagnosis and clinical correlation. Hum Pathol 2004; 35(12):1515–23.PubMedGoogle Scholar
  12. 12.
    Schmidt CS, Morrow WJ, Sheikh NA. Smart adjuvants. Expert Rev Vaccines 2007; 6(3):391–400.PubMedGoogle Scholar
  13. 13.
    Petrovsky N. Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine 2006; 24 Suppl. 2:S2–26–9.Google Scholar
  14. 14.
    Ott G, Barchfeld GL, Chernoff D et al. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol 1995; 6:277–96.PubMedGoogle Scholar
  15. 15.
    Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003; 2(2):197–203.PubMedGoogle Scholar
  16. 16.
    Patel P, Salapatek AM. Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine. Expert Rev Vaccines 2006; 5(5):617–29.PubMedGoogle Scholar
  17. 17.
    Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 2007; 6(2):133–40.PubMedGoogle Scholar
  18. 18.
    Persing DH, Coler RN, Lacy MJ et al. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol 2002; 10(10 Suppl):S32–7.Google Scholar
  19. 19.
    De Vendittis E, Palumbo G, Parlato G et al. A fluorimetric method for the estimation of the critical micelle concentration of surfactants, Anal Biochem 1981; 115(2):278–86.PubMedGoogle Scholar
  20. 20.
    Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004; 82(5):488–96.PubMedGoogle Scholar
  21. 21.
    Holmgren J, Adamsson J, Anjuere F et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CgP DNA. Immunol Lett 2005; 97(2):181–8.PubMedGoogle Scholar
  22. 22.
    Mesa C, Fernandez LE. Challenges facing adjuvants for cancer immunotherapy. Immunol Cell Biol 2004; 82(6):644–50.PubMedGoogle Scholar
  23. 23.
    O’Hagan DT, Ott GS, Van Nest G. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Mol Med Today 1997; 3(2):69–75.PubMedGoogle Scholar
  24. 24.
    Hisert KB, MacCoss M, Shiloh MU et al. A glutamate-alanine-leucine (EAL) domain protein of Salmonella controls bacterial survival in mice, antioxidant defence and killing of macrophages: role of cyclic diGMP. Mol Microbiol 2005; 56(5):1234–45.PubMedGoogle Scholar
  25. 25.
    O’Hagan DT. Recent advances in vaccine adjuvants for systemic and mucosal administration. J Pharm Pharmacol 1998; 50(1):1–10.PubMedGoogle Scholar
  26. 26.
    Kuroda Y, Nacionales DC, Akaogi J et al. Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomed Pharmacother 2004; 58(5):325–37.PubMedGoogle Scholar
  27. 27.
    Mellerup MT, Hahn GW, Poulsen LK et al. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy 2000; 30(10):1423–9.PubMedGoogle Scholar
  28. 28.
    Goswami AK, Mahajan RK, Nath R et al. How safe in 1% alum irrigation in controlling intractable vesical hemorrhage? J Urol 1993; 149(2):264–7.PubMedGoogle Scholar
  29. 29.
    Graham BS, Keefer MC, McElrath MJ et al. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Ann Intern Med 1996; 125(4):270–9.PubMedGoogle Scholar
  30. 30.
    Ruf BR, Colberg K, Frick M et al. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection 2004; 32(4):191–8.PubMedGoogle Scholar
  31. 31.
    Weeratna RD, McCluskie MJ, Xu Y et al. CpG DNA induces stronger immune responses with less oxicity than other adjuvants. Vaccine 2000; 18(17):1755–62.PubMedGoogle Scholar
  32. 32.
    Fujihashi K, Koga T, van Ginkel FW et al. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 2002; 20(19–20):2431–8.PubMedGoogle Scholar
  33. 33.
    van Ginkel FW, Jackson RJ, Yuki Y et al. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 2000; 165(9):4778–82.PubMedGoogle Scholar
  34. 34.
    Kensil CR. Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst 1996; 13(1–2):1–55.PubMedGoogle Scholar
  35. 35.
    Cox JT, Petry KU, Rylander E et al. Using imiquimod for genital warts in female patients. J Womens Health (Larchmt) 2004; 13(3):265–71.Google Scholar
  36. 36.
    Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv Drug Deliv Rev 2006; 58(1):68–89.PubMedGoogle Scholar
  37. 37.
    Kirk DD, Rempel R, Pinkhasov J et al. Application of Quillaja saponaria extracts as oral adjuvants for plant-made vaccines. Expert Opin Biol Ther 2004; 4(6):947–58.PubMedGoogle Scholar
  38. 38.
    Kensil CR, Wu JY, Soltysik S. Structural and immunological characterization of the vaccine adjuvant QS-21. Pharm Biotechnol 1995; 6:525–41.PubMedGoogle Scholar
  39. 39.
    McCluskie MJ, Weeratna RD. Novel adjuvant systems. Curr Drug Targets Infect Disord 2001; 1(3):263–71.PubMedGoogle Scholar
  40. 40.
    Morein B, Bengtsson KL. Immunomodulation by iscoms, immune stimulating complexes. Methods 1999; 19(1):94–102.PubMedGoogle Scholar
  41. 41.
    Kersten G, Hirschberg H. Antigen delivery systems. Expert Rev Vaccines 2004; 3(4):453–62.PubMedGoogle Scholar
  42. 42.
    Sjolander A, Cox JC, Barr IG. ISCOMs: an adjuvant with multiple functions. J Leukoc Biol 1998; 64(6):713–23.PubMedGoogle Scholar
  43. 43.
    Moser C, Metcalfe IC, Viret JF. Virosomal adjuvanted antigen delivery systems. Expert Rev Vaccines 2003; 2(2):189–96.PubMedGoogle Scholar
  44. 44.
    Felnerova D, Viret JF, Gluck R et al. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 2004; 15(6):518–29.PubMedGoogle Scholar
  45. 45.
    Bungener L, Huckriede A, Wilschut J et al. Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMs. Biosci Rep 2002; 22(2):323–38.PubMedGoogle Scholar
  46. 46.
    Gluck R, Burri KG, Metcalfe I. Adjuvant and antigen delivery properties of virosomes. Curr Drug Deliv 2005; 2(4):395–400.PubMedGoogle Scholar
  47. 47.
    Kirkley JE, Goldstein AL, Naylor PH. Adjuvant properties of montanide CSA 720 with a recombinant HIV P17 gap protein and synthetic peptide antigens. Scand J Immunol 1996; 43(4):431–8.PubMedGoogle Scholar
  48. 48.
    Dupuis L, Ascarateil S, Aucouturier J et al. SEPPIC vaccine adjuvants for poultry. Ann NY Acad Sci 2006; 1081:202–5.PubMedGoogle Scholar
  49. 49.
    Aucouturier J, Dupuis L, Deville S et al. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 2002; 1(1):111–8.PubMedGoogle Scholar
  50. 50.
    Charoenvit Y, Goel N, Whelan M et al. CEL-1000—a peptide with adjuvant activity for Th1 immune responses. Vaccine 2004; 22(19):2368–73.PubMedGoogle Scholar
  51. 51.
    Charoenvit Y, Brice GT, Bacon D et al. A small peptide (CEL-1000) derived from the beta-chain of the human major histocompatibility complex class II molecule induces complete protection against malaria in an antigen-independent manner. Antimicrob Agents Chemother 2004; 48(7):2455–63.PubMedGoogle Scholar
  52. 52.
    Allan E, Wren BW. Genes to genetic immunization: identification of bacterial vaccine candidates. Methods 2003; 31(3):193–8.PubMedGoogle Scholar
  53. 53.
    Workman P. New drug targets for genomic cancer therapy: successes, limitations, opportunities and future challenges. Curr Cancer Drug Targets 2001; 1(1):33–47.PubMedGoogle Scholar
  54. 54.
    Schneider J, Gilbert SC, Hannan CM et al. Induction of CD8+T-cells using heterologous prime-boost immunisation strategies. Immunol Rev 1999; 170:29–38.PubMedGoogle Scholar
  55. 55.
    Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3(2):196–200.PubMedGoogle Scholar
  56. 56.
    van Duin D, Medzhitov R, Shaw AC. Triggering TLR signaling in vaccination. Trends Immunol 2006; 27(1):49–55.PubMedGoogle Scholar
  57. 57.
    Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124(4):783–801.PubMedGoogle Scholar
  58. 58.
    Schwarz K, Storni T, Manolova V et al. Role of Toll-like receptors in costimulating cytotoxic T-cell responses. Eur J Immunol 2003; 33(6):1465–70.PubMedGoogle Scholar
  59. 59.
    Ishii KJ, Coban C, Akira S. Manifold mechanisms of toll-like receptor-ligand recognition. J Clin Immunol 2005; 25(6):511–21.PubMedGoogle Scholar
  60. 60.
    Chisholm D, Libet L, Hayashi T et al. Airway peptidoglycan and immunostimulatory DNA exposures have divergent effects on the development of airway allergen hypersensitivities. J Allergy Clin Immunol 2004; 113(3):448–54.PubMedGoogle Scholar
  61. 61.
    Johansen P, Senti G, Martinez Gomez JM et al. Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clin Exp Allergy 2005; 35(12):1591–8.PubMedGoogle Scholar
  62. 62.
    Hessel EM, Chu M, Lizcano JO et al. Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction. J Exp Med 2005; 202(11):1563–73.PubMedGoogle Scholar
  63. 63.
    Dabbagh K, Lewis DB. Toll-like receptors and T-helper-1/T-helper-2 responses. Curr Opin Infect Dis 2003; 16(3):199–204.PubMedGoogle Scholar
  64. 64.
    Gangloff SC, Guenounou M. Toll-like receptors and immune response in allergic disease. Clin Rev Allergy Immunol 2004; 26(2):115–25.PubMedGoogle Scholar
  65. 65.
    Patel M, Xu D, Kewin P et al. TLR2 agonist ameliorates established allergic airway inflammation by promoting Th1 response and not via regulatory T-cells. J Immunol 2005; 174(12):7558–63.PubMedGoogle Scholar
  66. 66.
    Liu H, Komai-Koma M, Xu D et al. Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T-cells. Proc Natl Acad Sci USA 2006; 103(18):7048–53.PubMedGoogle Scholar
  67. 67.
    Spohn R, Buwitt-Beckmann U, Brock R et al. Synthetic lipopeptide adjuvants and Toll-like receptor 2—structure-activity relationships. Vaccine 2004; 22(19):2494–9.PubMedGoogle Scholar
  68. 68.
    Rharbaoui F, Westendorf A, Link C et al. The Mycoplasma-derived macrophage-activating 2-kilodalton lipopeptide triggers global immune activation on nasal mucosa-associated lymphoid tissues. Infect Immun 2004; 72(12):6978–86.PubMedGoogle Scholar
  69. 69.
    Katz J, Zhang P, Martin M et al. Toll-like receptor 2 is required for inflammatory responses to Francisella tularensis LVS. Infect Immun 2006; 74(5):2809–16.PubMedGoogle Scholar
  70. 70.
    Mitsunari M, Yoshida S, Shoji T et al. Macrophage-activating lipopetide-2 induces cyclooxygenase-2 and prostaglandin E(2) via toll-like receptor 2 in human placental trophoblas T-cells. J Reprod Immunol 2006; 72(1–2):46–59.PubMedGoogle Scholar
  71. 71.
    Espuelas S, Roth A, Thumann C et al. Effect of synthetic lipopeptides formulated in liposomes on the maturation of human dendritic cells. Mol Immunol 2005; 42(6):721–9.PubMedGoogle Scholar
  72. 72.
    Borsutzky S, Fiorelli V, Ebensen T et al. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. Eur J Immunol 2003; 33(0014-2980 VI-33 IP-6 DP-2003): 1548–56.PubMedGoogle Scholar
  73. 73.
    Azuma I, Seya T. Development of immunoadjuvants for immunotherapy of cancer. Int Immunopharmacol 2001; 1(7):1249–59.PubMedGoogle Scholar
  74. 74.
    Skidmore BJ, Chiller JM, Morrison DC et al. Immunologic properties of bacterial lipopolysaccharide (LPS): correlation between the mitogenic, adjuvant and immunogenic activities. J Immunol 1975; 114(2 pt 2):770–5.PubMedGoogle Scholar
  75. 75.
    Skidmore BJ, Chiller JM, Weigle WO. Immunologic properties of bacterial lipopolysaccharide (LPS). IV. Cellular basis of the unresponsiveness of C3H/HeJ mouse spleen cells to LPS-induced mitogenesis. J Immunol 1977; 118(1):274–81.PubMedGoogle Scholar
  76. 76.
    Skidmore BJ, Chiller JM, Weigle WO et al. Immunologic properties of bacterial lipopolysaccharide (LPS). III. Genetic linkage between the in vitro mitogenic and in vivo adjuvant properties of LPS. J Exp Med 1976; 143(1):143–50.PubMedGoogle Scholar
  77. 77.
    Skidmore BJ, Morrison DC, Chiller JM et al. Immunologic properties of bacterial lipopolysaccharide (LPS). II. The unresponsiveness of C3H/HeJ Mouse spleen cells to LPS-induced mitogenesis is dependent on the method used to extract LPS. J Exp Med 1975; 142(6):1488–508.PubMedGoogle Scholar
  78. 78.
    Poltorak A, He X, Smirnova I et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282(5396):2085–8.PubMedGoogle Scholar
  79. 79.
    Mata-Haro V, Cekic C, Martin M et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007; 316(5831):1628–32.PubMedGoogle Scholar
  80. 80.
    Baldridge JR, McGowan P, Evans JT et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 2004; 4(7):1129–38.PubMedGoogle Scholar
  81. 81.
    Sinet M, Pocidalo JJ. [Are immunomodulators capable to improve the activity of nucleoside antiretroviral agents?] Pathol Biol (Paris) 1993; 41(8 Pt 2):794–8.Google Scholar
  82. 82.
    Robinson RA, DeVita VT, Levy HB et al. A phase I–II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J Natl Cancer Inst 1976; 57(3):599–602.PubMedGoogle Scholar
  83. 83.
    Adams M, Navabi H, Jasani B et al. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically nontoxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R). Vaccine 2003; 30; 21(7–8):787–90.PubMedGoogle Scholar
  84. 84.
    Huleatt JW, Jacobs AR, Tang J et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007; 25(4):763–75.PubMedGoogle Scholar
  85. 85.
    Honko AN, Sriranganathan N, Lees CJ et al. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun 2006; 74(2):1113–20.PubMedGoogle Scholar
  86. 86.
    Szabo C. Role of flagellin in the pathogenesis of shock and acute respiratory distress syndrome: therapeutic opportunities. Crit Care Med 2003; 31(1 Suppl):S39–45.Google Scholar
  87. 87.
    Langford MP, Chen D, Gosslee J et al. Intracameral toxicity of bacterial components muramyl dipeptide and staurosporine: ciliary cyst formation, epithelial cell apoptosis and necrosis. Cutan Ocul Toxicol 2006; 25(2):85–101.PubMedGoogle Scholar
  88. 88.
    Saha S, Takeshita F, Matsuda T et al. Blocking of the TLR5 Activation Domain Hampers Protective Potential of Flagellin DNA Vaccine. J Immunol 2007; 179(2):1147–54.PubMedGoogle Scholar
  89. 89.
    Wu JJ, Huang DB, Tyring SK. Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antiviral Res 2004; 64(2):79–83.PubMedGoogle Scholar
  90. 90.
    Gupta AK, Browne M, Bluhm R. Imiquimod: a review. J Cutan Med Surg 2002; 6(6):554–60.PubMedGoogle Scholar
  91. 91.
    Schonberger O, Hirst TR, Pines O. Targeting and assembly of an oligomeric bacterial enterotoxoid in the endoplasmic reticulum of Saccharomyces cerevisiae. Mol Microbiol 1991; 5(11):2663–71.PubMedGoogle Scholar
  92. 92.
    Syed TA. A review of the applications of imiquimod: a novel immune response modifier. Expert Opin Pharmacother 2001; 2(5):877–82.PubMedGoogle Scholar
  93. 93.
    Thomsen LL, Topley P, Daly MG et al. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 2004; 22(13–14):1799–809.PubMedGoogle Scholar
  94. 94.
    Carrington AC, Secombes CJ. A review of CpGs and their relevance to aquaculture. Vet Immunol Immunopathol 2006; 112(3–4):87–101.PubMedGoogle Scholar
  95. 95.
    Jurk M, Heil F, Vollmer J et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002; 3(6):499.PubMedGoogle Scholar
  96. 96.
    Ioannou XP, Griebel P, Mena A et al. Safety of CpG oligodeoxynucleotides in veterinary species. Antisense Nucleic Acid Drug Dev 2003; 13(3):157–67.PubMedGoogle Scholar
  97. 97.
    Scheule RK. The role of CpG motifs in immunostimulation and gene therapy. Adv Drug Deliv Rev 2000; 44(2–3):119–34.PubMedGoogle Scholar
  98. 98.
    Gurunathan S, Klinman DM, Seder RA. DNA Vaccines: Immunology, Application and Optimization. Annu Rev Immunol 2000; 18(1):927–74.PubMedGoogle Scholar
  99. 99.
    Dalpke A, Zimmermann S, Heeg K. CpG DNA in the prevention and treatment of infections. BioDrugs 2002; 16(6):419–31.PubMedGoogle Scholar
  100. 100.
    Arce S, Nawar HF, Russell MW et al. Differential binding of Escherichia coli, enterotoxins LT-IIa and LT-IIb and of cholera toxin elicits differences in apoptosis, proliferation and activation of lymphoid cells. Infect Immun 2005; 73(5):2718–27.PubMedGoogle Scholar
  101. 101.
    Fukuta S, Magnani JL, Twiddy EM et al. Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTh-I, LT-IIa, and LT-IIb. Infect Immun 1988; 56(7):1748–53.PubMedGoogle Scholar
  102. 102.
    Johnson SM, Lerche NW, Pappagianis D et al. Antigenicity, safety and efficacy of a recombinant coccidioidomycosis vaccine in cynomolgus maques (Macaca fascicularis). Ann NY Acad Sci 2007.Google Scholar
  103. 103.
    Schnitzler AC, Burke JM, Wetzler LM. Induction of cell signaling events by the cholera toxin B subunit in antigen-presenting cells. Infect Immun 2007; 75(6):3150–9.PubMedGoogle Scholar
  104. 104.
    Kawamura YI, Kawashima R, Shirai Y et al. Cholera toxin activates dendritic cells through dependence on GM1-ganglioside which is mediated, by NF-κB translocation. Eur J Immunol 2003; 33(11):3205–12.PubMedGoogle Scholar
  105. 105.
    Williams NA. Immune modulation by the cholera-like enterotoxin B-subunits: from adjuvant to immunotherapeutic. Int J Med Microbiol 2000; 290(4–5):447–53.PubMedGoogle Scholar
  106. 106.
    Pizza M, Giuliani MM, Fontana MR, et al. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 2001; 19(17–19):2534–41.PubMedGoogle Scholar
  107. 107.
    Plant A, Williams NA. Modulation of the immune response by the cholera-like enterotoxins. Curr Top Med Chem 2004; 4(5):509–19.PubMedGoogle Scholar
  108. 108.
    Lalazar G, Preston S, Zigmond E et al. Glycolipids as immune modulatory tools. Mini Rev Med Chem 2006; 6(11):1249–53.PubMedGoogle Scholar
  109. 109.
    Chen YG, Choisy-Rossi CM, Holl TM et al. Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. J Immunol 2005; 174(3):1196–204.PubMedGoogle Scholar
  110. 110.
    Van Kaer L. Natural killer T-cells as targets for immunotherapy of autoimmune diseases. Immunol Cell Biol 2004; 82(3):315–22.PubMedGoogle Scholar
  111. 111.
    Yamamura T, Miyamoto K, Illes Z et al. NKT cell-stimulating synthetic glycolipids as potential therapeutics for autoimmune disease. Curr Top. Med Chem 2004; 4(5):561–7.PubMedGoogle Scholar
  112. 112.
    Parekh VV, Singh AK, Wilson MT et al. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha-and beta-anomeric glycolipids. J Immunol 2004; 173(6):3693–706.PubMedGoogle Scholar
  113. 113.
    Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC et al. Natural killer T-cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 2002; 195(5):617–24.PubMedGoogle Scholar
  114. 114.
    Nishimura T, Kitamura H, Iwakabe K et al. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T-lymphocytes. Int Immunol 2000; 12(7):987–94.PubMedGoogle Scholar
  115. 115.
    Sakai T, Ehara H, Koezuka Y. Synthesis of NBD-alpha-galactosylceramide and its immunologic properties. Org Lett 1999; 1(3):359–61.PubMedGoogle Scholar
  116. 116.
    Yamauchi A, Dai SY, Nakagawa R et al. [Galectin-9 induces maturation of human monocyte-derived dendritic cells]. Nihon Rinsho Meneki Gakkai Kaishi 2005; 28(6):381–8.PubMedGoogle Scholar
  117. 117.
    Youn HJ, Ko SY, Lee KA et al. A single intransal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine 2007; 25(28):5189–98.PubMedGoogle Scholar
  118. 118.
    Sakaue G, Hiroi T, Nakagawa Y et al. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses. J Immunol 2003; 170(1):495–502.PubMedGoogle Scholar
  119. 119.
    Ebensen T, Link C, Riese P et al. A Pegylated Derivative of {alpha}-Galactosylceramide Exhibits Improved Biological Properties. J Immunol 2007; 179(4):2065–73.PubMedGoogle Scholar
  120. 120.
    Wigginton JM, Wiltrout RH. IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside. Expert Opin Biol Ther 2002; 2(5):513–24.PubMedGoogle Scholar
  121. 121.
    Beadling C, Slifka MK. Regulation of innate and adaptive immune responses by the related cytokines IL-12, IL-23 and IL-27. Arch Immunol Ther Exp (Warsz) 2006; 54(1):15–24.Google Scholar
  122. 122.
    Margolin KA. Interleukin-2 in the treatment of renal cancer. Semin Oncol 2000; 27(2):194–203.PubMedGoogle Scholar
  123. 123.
    Shanmugham LN, Petrarca C, Frydas S et al. IL-15 an immunoregulatory and anti-cancer cytokine. Recent advances. J Exp Clin Cancer Res 2006; 25(4):529–36.PubMedGoogle Scholar
  124. 124.
    Yan L, Anderson GM, DeWitte M et al. Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. Eur J Cancer 2006; 42(6):793–802.PubMedGoogle Scholar
  125. 125.
    Flanagan K, Kaufman HL. Chemokines in tumor immunotherapy. Front Biosci 2006; 11:1024–30.PubMedGoogle Scholar
  126. 126.
    Slettenaar VI, Wilson JL. The chemokine network: a target in cancer biology? Adv Drug Deliv Rev 2006; 58(8):962–74.PubMedGoogle Scholar
  127. 127.
    Dell’Agnola C, Biragyn A. Clinical utilization of chemokines to combat cancer: the double-edged sword. Expert Rev Vaccines 2007; 6(2):267–83.Google Scholar
  128. 128.
    Anton P, Kirchner H, Jonas U et al. Cytokines and tumor vaccination. Cancer Biother Radiopharm 1996; 11(5):315–8.PubMedGoogle Scholar
  129. 129.
    Parmiani G, Arienti F, Sule-Suso J et al. Cytokine-based gene therapy of human tumors. An overview. Folia Biol (Praha) 1996; 42(6):305–9.Google Scholar
  130. 130.
    Villinger F. Cytokines as clinical adjuvants: how far are we? Expert Rev Vaccines 2003; 2(2):317–26.PubMedGoogle Scholar
  131. 131.
    Ellouz F, Adam A, Ciorbaru R et al. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun 1974; 59(4):1317–25.PubMedGoogle Scholar
  132. 132.
    Inohara N, Ogura Y, Fontalba A et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn’s disease. J Biol Chem 2003; 278(8):5509–12.PubMedGoogle Scholar
  133. 133.
    Uehori J, Fukase K, Akazawa T et al. Dendritic cell maturation induced by muramyl dipeptide (MDP) derivatives: monoacylated MDP confers TLR2/TLR4 activation. J Immunol 2005; 174(11):7096–103.PubMedGoogle Scholar
  134. 134.
    Ferwerda G, Girardin SE, Kullberg BJ et al. NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathog 2005; 1(3):279–85.PubMedGoogle Scholar
  135. 135.
    Sevcik J, Masek K. The interaction of immunomodulatory muramyl dipeptide with peripheral 5-HT receptors: overview of the current state. Int J Immunopharmacol 1999; 21(3):227–32.PubMedGoogle Scholar
  136. 136.
    Jiang ZH, Koganty RR. Synthetic vaccines: the role of adjuvants in immune targeting. Curr Med Chem 2003; 10(15):1423–39.PubMedGoogle Scholar
  137. 137.
    O’Reilly T, Zak O. Enhancement of the effectiveness of antimicrobial therapy by muramyl peptide immunomodulators. Clin Infect Dis 1992; 14(5):1100–9.PubMedGoogle Scholar
  138. 138.
    Kaliuzhin OV. [Muramyl dipeptide derivatives in experimental and clinical use]. Zh Mikrobiol Epidemiol Immunobiol 1998:104–8.Google Scholar
  139. 139.
    Hui GS. Liposomes, muramyl dipeptide derivatives and nontoxic lipid A derivatives as adjuvants for human malaria vaccines. Am J Trop Med Hyg 1994; 50(4 Suppl):41–51.PubMedGoogle Scholar
  140. 140.
    Becker PD, Norder M, Guzman CA et al. Immune modulator adamantylamide dipeptide stimulates efficient major histocompatibility complex class I-restricted responses in mice. Clin Vaccine Immunol 2007; 14(5):538–43.PubMedGoogle Scholar
  141. 141.
    Becker PD, Bertot GM, Souss D et al. Intranasal vaccination with recombinant outer membrane protein CD and adamantylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhalis in an experimental murine model. Infect Immun 2007; 75(4):1778–84.PubMedGoogle Scholar
  142. 142.
    Bertot GM, Becker PD, Guzman CA et al. Intranasal vaccination with recombinant P6 protein and adamantylamide dipeptide as mucosal adjuvant confers efficient protection against otitis media and lung infection by nontypeable Haemophilus influenzae. J Infect Dis 2004; 189(7):1304–12.PubMedGoogle Scholar
  143. 143.
    Becker PD, Corral RS, Guzman CA et al. Adamantylamide dipeptide as effective immunoadjuvant in rabbits and mice. Vaccine 2001; 19(32):4603–9.PubMedGoogle Scholar
  144. 144.
    Subauste CS. CD154 and type-1 cytokine response: from hyper IgM syndrome to human immunodeficiency virus infection. J Infect Dis 2002; 185Suppl. 1:S83–9.Google Scholar
  145. 145.
    Barr TA, Carlring J, Heath AW. Costimulatory agonists as immunological adjuvants. Vaccine 2006; 24(17):3399–407.PubMedGoogle Scholar
  146. 146.
    Cairing J, Barr T, Heath AW. Adjuvanticity of anti-cD40 in vaccine development. Curr Opin Mol Ther 2005; 7(1):73–7.PubMedGoogle Scholar
  147. 147.
    Ahlers JD, Belyakov IM, Berzofsky JA. Cytokine, chemokine and costimulatory molecule modulation to enhance efficacy of HIV vaccines. Curr Mol Med 2003; 3(3):285–301.PubMedGoogle Scholar
  148. 148.
    Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T-cell costimulatory molecule OX40. Nat Rev Immunol 2004; 4(6):420–31.PubMedGoogle Scholar
  149. 149.
    Dohring C, Angman L, Spagnoli G et al. T-helper-and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int J Cancer 1994; 57(5):754–9.PubMedGoogle Scholar
  150. 150.
    Chen L, McGowan P, Ashe S et al. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer Res 1994; 54(20):5420–3.PubMedGoogle Scholar
  151. 151.
    Chen L, McGowan P, Ashe S et al. Tumor immunogenicity determines the effect of B7 costimulation on T-cell-mediated tumor immunity. J Exp Med 1994; 179(2):523–32.PubMedGoogle Scholar
  152. 152.
    Kalus RM, Kantor JA, Gritz L et al. The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation. Vaccine 1999; 17(7–8):893–903.PubMedGoogle Scholar
  153. 153.
    Romling U, Amikam D. Cyclic di-GMP as a second messenger. Curr Opin Microbiol 2006; 9(2):218–28.PubMedGoogle Scholar
  154. 154.
    Romling U, Gomelsky M, Galperin MY. C-di-GMP: the dawning of a novel bacterial signalling system. Mol Microbiol 2005; 57(3):629–39.PubMedGoogle Scholar
  155. 155.
    Karaolis DK, Cheng K, Lipsky M et al. 3′, 5′-Cyclic diguanylic acid (c-di-GMP) inhibits basal and growth factor-stimulated human colon cancer cell proliferation. Biochem Biophys Res Commun 2005; 329(1):40–5.PubMedGoogle Scholar
  156. 156.
    Ebensen T, Schulze K, Riese P et al. The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties. Vaccine 2007; 25(8):1464–9.PubMedGoogle Scholar
  157. 157.
    Ebensen T, Schulze K, Riese P et al. The bacterial second messenger cdiGMP exhibits promising activity as mucosal adjuvant. Clin Vaccine Immunol 2007; 14(8):952–8.PubMedGoogle Scholar
  158. 158.
    Karaolis DK, Means TK, Yang D et al. Bacterial c-di-GMP is an immunostimulatory molecule. J Immunol 2007; 178(4):2171–81.PubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2009

Authors and Affiliations

  1. 1.Department of Vaccinology and Applied MicobiologyHelmholtz Centre for Infection ResearchBraunschweigGermany

Personalised recommendations